Inogen, Inc (INGN) Director Heath Lukatch Sells 2,500 Shares
Inogen, Inc (NASDAQ:INGN) Director Heath Lukatch sold 2,500 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $97.44, for a total transaction of $243,600.00. Following the sale, the director now owns 2,500 shares in the company, valued at approximately $243,600. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Inogen, Inc (NASDAQ:INGN) traded up 2.24% during mid-day trading on Friday, hitting $103.05. 246,209 shares of the stock traded hands. The company has a market cap of $2.14 billion, a P/E ratio of 89.45 and a beta of 1.02. Inogen, Inc has a 12 month low of $50.24 and a 12 month high of $104.06. The company’s 50 day moving average is $94.64 and its 200 day moving average is $86.04.
Inogen (NASDAQ:INGN) last released its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. During the same quarter in the previous year, the firm earned $0.25 earnings per share. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, analysts expect that Inogen, Inc will post $1.21 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Inogen, Inc (INGN) Director Heath Lukatch Sells 2,500 Shares” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/08/inogen-inc-ingn-director-heath-lukatch-sells-2500-shares.html.
Several analysts have recently weighed in on the stock. Needham & Company LLC lowered their price objective on shares of Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a research report on Thursday, June 8th. BidaskClub cut shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research cut shares of Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, J P Morgan Chase & Co raised their price objective on shares of Inogen to $102.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $91.60.
A number of institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd purchased a new stake in Inogen during the second quarter valued at $442,000. Koch Industries Inc. raised its stake in Inogen by 19,485.8% during the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after purchasing an additional 653,747 shares in the last quarter. Verition Fund Management LLC purchased a new stake in Inogen during the second quarter valued at $280,000. Piedmont Investment Advisors LLC purchased a new stake in Inogen during the second quarter valued at $336,000. Finally, Ameritas Investment Partners Inc. raised its stake in Inogen by 6.1% during the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 86 shares in the last quarter.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.